Switch theme
Sign up to access all valuation multiples
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
1983
664
LTM Revenue $230M
LTM EBITDA $66.0M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LeMaitre Vascular has a last 12-month revenue (LTM) of $230M and a last 12-month EBITDA of $66.0M.
In the most recent fiscal year, LeMaitre Vascular achieved revenue of $220M and an EBITDA of $66.8M.
LeMaitre Vascular expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LeMaitre Vascular valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $230M | XXX | $220M | XXX | XXX | XXX |
| Gross Profit | $159M | XXX | $151M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $66.0M | XXX | $66.8M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $54.6M | XXX | $52.3M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $46.4M | XXX | $44.0M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $142M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LeMaitre Vascular's stock price is $82.
LeMaitre Vascular has current market cap of $1.9B, and EV of $1.7B.
See LeMaitre Vascular trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $1.9B | XXX | XXX | XXX | XXX | $2.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LeMaitre Vascular has market cap of $1.9B and EV of $1.7B.
LeMaitre Vascular's trades at 7.9x EV/Revenue multiple, and 26.1x EV/EBITDA.
Equity research analysts estimate LeMaitre Vascular's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LeMaitre Vascular has a P/E ratio of 40.0x.
See valuation multiples for LeMaitre Vascular and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBITDA | 26.4x | XXX | 26.1x | XXX | XXX | XXX |
| EV/EBIT | 31.9x | XXX | 33.3x | XXX | XXX | XXX |
| EV/Gross Profit | 10.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.0x | XXX | 42.2x | XXX | XXX | XXX |
| EV/FCF | 36.3x | XXX | 46.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLeMaitre Vascular's last 12 month revenue growth is 10%
LeMaitre Vascular's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
LeMaitre Vascular's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LeMaitre Vascular's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LeMaitre Vascular and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LeMaitre Vascular acquired XXX companies to date.
Last acquisition by LeMaitre Vascular was XXXXXXXX, XXXXX XXXXX XXXXXX . LeMaitre Vascular acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LeMaitre Vascular founded? | LeMaitre Vascular was founded in 1983. |
| Where is LeMaitre Vascular headquartered? | LeMaitre Vascular is headquartered in United States of America. |
| How many employees does LeMaitre Vascular have? | As of today, LeMaitre Vascular has 664 employees. |
| Who is the CEO of LeMaitre Vascular? | LeMaitre Vascular's CEO is Mr. George W. Lemaitre. |
| Is LeMaitre Vascular publicy listed? | Yes, LeMaitre Vascular is a public company listed on NAS. |
| What is the stock symbol of LeMaitre Vascular? | LeMaitre Vascular trades under LMAT ticker. |
| When did LeMaitre Vascular go public? | LeMaitre Vascular went public in 2006. |
| Who are competitors of LeMaitre Vascular? | Similar companies to LeMaitre Vascular include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of LeMaitre Vascular? | LeMaitre Vascular's current market cap is $1.9B |
| What is the current revenue of LeMaitre Vascular? | LeMaitre Vascular's last 12 months revenue is $230M. |
| What is the current revenue growth of LeMaitre Vascular? | LeMaitre Vascular revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of LeMaitre Vascular? | Current revenue multiple of LeMaitre Vascular is 7.6x. |
| Is LeMaitre Vascular profitable? | Yes, LeMaitre Vascular is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LeMaitre Vascular? | LeMaitre Vascular's last 12 months EBITDA is $66.0M. |
| What is LeMaitre Vascular's EBITDA margin? | LeMaitre Vascular's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of LeMaitre Vascular? | Current EBITDA multiple of LeMaitre Vascular is 26.4x. |
| What is the current FCF of LeMaitre Vascular? | LeMaitre Vascular's last 12 months FCF is $48.0M. |
| What is LeMaitre Vascular's FCF margin? | LeMaitre Vascular's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of LeMaitre Vascular? | Current FCF multiple of LeMaitre Vascular is 36.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
